Open Nav

Sinfonia Biotherapeutics, Inc.

  • Bob Blomquist, Sinfonia Biotherapeutics, Inc.

To connect with potential investors and network with potential partners.

  • Date:Wednesday, October 17
  • Time:9:15 AM - 9:30 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Sinfonia Biotherapeutics is pioneering the development of novel, bioreactor-delivered drug treatments for familial & genetically-defined neurodegenerative disorders within frontotemporal lobar dementia (FTD), Alzheimer’s & Parkinson’s disorders. Our approach to developing orphan drug therapies is targeting patient subtypes and disease mechanisms that are genetically defined. To deliver our first-in-class disease-modifying therapies, we are employing our proprietary, implantable bioreactor device with cells engineered to manufacture single or multiple therapeutic factors locally within the brain. We have two drug therapies presently in preclinical development, iProg and MTA. The lead indication for our most advanced developmental therapy, iProg, is treatment for GRN-related FTD through restoration of progranulin levels. By developing patient-targeted therapies that are delivered by our bioreactor technology, we will launch breakthrough treatments for well-defined dementias and beyond.
  • Company
  • Company HQ City:Boulder
  • Company HQ Country:United States
  • Company HQ State:Colorado                   
  • CEO/Top Company Official:Robert Blomquist
  • Year Founded:2017
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development :iProg treatment for GRN-related FTD
  • Development Phase of Primary Product:Pre-Clinical
  • Additional Information/Comments:POC: We have Proof of concept results for our bioreactor encapsulated cell delivery platform demonstrating delivery of progranulin and other biologics in animal models and in humans. Competitive Advantages: For iProg and its lead indication of GRN-related FTD, we are aware of some competitive approaches to increase progranulin levels in the brain. Our approach is unique in targeting the underlying, genetically-defined disease mechanism of progranulin haploinsufficiency. Indeed, we are developing direct treatment of progranulin deficiency by bioreactor delivery of progranulin to affected brain tissues, thus avoiding blood-brain barrier issues, with negligible systemic exposure. Traction: We are gaining traction in the market, as demonstrated by the grants we have secured from patient advocacy groups, collaborations with key opinion leaders and FTD research networks and partnerships.
  • Total Amount Raised to Date, In All Rounds:$1.52 M USD
Bob Blomquist
Sinfonia Biotherapeutics, Inc.